The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
PDE4 inhibitors: current status
Open accessAbstract
Phosphodiesterase4 inhibitors are currently under development for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease. The rationale for the development of this drug class stems from our understanding of the role of PDE4 in suppressing the function of a range of inflammatory and resident cells thought to contribute toward the pathogenesis of these diseases. Similarly, numerous preclinical in vivo studies have shown that PDE4 inhibitors suppress characteristic features of these diseases, namely, cell recruitment, activation of inflammatory cells and physiological changes in lung function in response to a range of insults to the airways. These potentially beneficial actions of PDE4 inhibitors have been successfully translated in phase II and III clinical trials with roflumilast and cilomilast. However, dose limiting side effects of nausea, diarrhoea and headache have tempered the enthusiasm of this drug class for the treatment of these respiratory diseases. A number of strategies are currently being pursued in attempts to improve clinical efficacy and reduce side effects, including delivery via the inhaled route, and/or development of non‐emetic PDE4 inhibitors and mixed PDE inhibitors. British Journal of Pharmacology(2008)155, 308–315; doi:fn1; published online 28 July 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenosine 3‘,5‘-Phosphate in Biological Materials
Butcher, R. W., & Sutherland, E. W. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60316-3 · Cited by 2,077
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
How corticosteroids control inflammation: Quintiles Prize Lecture 2005
Barnes, P. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706736 · Cited by 838
Phosphodiesterase Isozymes: Molecular Targets for Novel Antiasthma Agents
TORPHY, T. J. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9708012 · Cited by 657
Keynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635
Sildenafil, a novel effective oral therapy for male erectile dysfunction
Boolell, M., Gepi‐Attee, S., Gingell, J. C., & Allen, M. J. (1996) · British Journal of Urology · doi:10.1046/j.1464-410x.1996.10220.x · Cited by 564
Histone acetylation and deacetylation: importance in inflammatory lung diseases
Barnes, P. J., Adcock, I. M., & Ito, K. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00117504 · Cited by 564
Lehnart, S. E., Wehrens, X. H. T., Reiken, S., Warrier, S., Belevych, A. E., Harvey, R. D., Richter, W., Jin, S.-L. C., Conti, M., & Marks, A. R. (2005) · Cell · doi:10.1016/j.cell.2005.07.030 · Cited by 517
Epithelium dysfunction in asthma
Holgate, S. T. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.10.025 · Cited by 489
Rabe, K. F., Bateman, E. D., O'Donnell, D., Witte, S., Bredenbröker, D., & Bethke, T. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67100-0 · Cited by 475
Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases
Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C., Tabrizizad, M., Gillette, S., Ibrahim, P. N., et al. (2004) · Structure · doi:10.1016/j.str.2004.10.004 · Cited by 432
Anti-inflammatory effects of low-dose oral theophylline in atopic asthma
Sullivan, P., Jaffar, Z., Page, C., Costello, J., Bekir, S., & Jeffery, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90127-9 · Cited by 403
Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro
Hatzelmann, A., & Schudt, C. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29537-9 · Cited by 398
Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity
Xu, R. X., Hassell, A. M., Vanderwall, D., Lambert, M. H., Holmes, W. D., Luther, M. A., Rocque, W. J., Milburn, M. V., Zhao, Y., Ke, H., et al. (2000) · Science · doi:10.1126/science.288.5472.1822 · Cited by 335
Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Sanchez-Toril, F., McIvor, A., Teichmann, P., Bredenbroeker, D., & Fabbri, L. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200610-1563oc · Cited by 325
Houslay, M. D., Baillie, G. S., & Maurice, D. H. (2007) · Circulation Research · doi:10.1161/01.res.0000261934.56938.38 · Cited by 317
Grootendorst, D. C., Gauw, S. A., Verhoosel, R. M., Sterk, P. J., Hospers, J. J., Bredenbroker, D., Bethke, T. D., Hiemstra, P. S., & Rabe, K. F. (2007) · Thorax · doi:10.1136/thx.2006.075937 · Cited by 286
Weinberger, M., & Hendeles, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342107 · Cited by 274
Robichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15506 · Cited by 267 · cited 4×
“Deletion of PDE4D and not PDE4B reduced the duration of anaesthesia induced by xylazine, compared with wild-type mice, and second, the ability of PDE4 inhibitors to shorten xylazine-induced anaesthesia was impaired in PDE4D but not PDE4B knockout mice (Robichaud et al., 2002b).”
BackgroundMethodResultInfluentialRobichaud, A., Stamatiou, P. B., Jin, S.-L. C., Lachance, N., MacDonald, D., Laliberté, F., Liu, S., Huang, Z., Conti, M., & Chan, C.-C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215506 · Cited by 259
DNA antisense therapy for asthma in an animal model
Nyce, J. W., & Metzger, W. J. (1997) · Nature · doi:10.1038/385721a0 · Cited by 257
In Vivo Efficacy in Airway Disease Models of Roflumilast, a Novel Orally Active PDE4 Inhibitor
Bundschuh, D. S., Eltze, M., Barsig, J., Wollin, L., Hatzelmann, A., & Beume, R. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29538-0 · Cited by 236
Pérez-Torres, S., Miró, X., Palacios, J. M., Cortés, R., Puigdoménech, P., & Mengod, G. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00097-1 · Cited by 229
Cherry, J. A., & Davis, R. L. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990503)407:2<287::aid-cne9>3.0.co;2-r · Cited by 215
Gross, P. M., Wall, K. M., Pang, J. J., Shaver, S. W., & Wainman, D. S. (1990) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1990.259.6.r1131 · Cited by 206
Roflumilast Fully Prevents Emphysema in Mice Chronically Exposed to Cigarette Smoke
Martorana, P. A., Beume, R., Lucattelli, M., Wollin, L., & Lungarella, G. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1549oc · Cited by 194
Ariga, M., Neitzert, B., Nakae, S., Mottin, G., Bertrand, C., Pruniaux, M. P., Jin, S.-L. C., & Conti, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7531 · Cited by 181
Takahashi, M., Terwilliger, R., Lane, C., Mezes, P. S., Conti, M., & Duman, R. S. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-02-00610.1999 · Cited by 176
Hansen, G., Jin, S.-L. C., Umetsu, D. T., & Conti, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6751 · Cited by 154
Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic Asthma
Kumar, R. K., Herbert, C. A., Thomas, P. S., Wollin, L., Beume, R., Yang, M., Webb, D. C., & Foster, P. S. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053819 · Cited by 146
Gantner, F., Kupferschmidt, R., Schudt, C., Wendel, A., & Hatzelmann, A. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701124 · Cited by 145
PDE4D plays a critical role in the control of airway smooth muscle contraction
Méhats, C., Jin, S.-L. C., Wahlstrom, J., Law, E. C., Umetsu, D. T., & Conti, M. (2003) · The FASEB Journal · doi:10.1096/fj.03-0274com · Cited by 142
Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides
Carpenter, D. O., Briggs, D. B., Knox, A. P., & Strominger, N. L. (1988) · Journal of Neurophysiology · doi:10.1152/jn.1988.59.2.358 · Cited by 138
Dunkern, T. R., Feurstein, D., Rossi, G. A., Sabatini, F., & Hatzelmann, A. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.036 · Cited by 135
PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
Robichaud, A., Savoie, C., Stamatiou, P. B., Tattersall, F. D., & Chan, C. C. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00142-8 · Cited by 131
Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease
Spina, D. (2003) · Drugs · doi:10.2165/00003495-200363230-00002 · Cited by 130
Self-citationKanehiro, A., Ikemura, T., Mäkelä, M. J., Lahn, M., Joetham, A., Dakhama, A., & Gelfand, E. W. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.1.2001118 · Cited by 127
Timmer, W., Leclerc, V., Birraux, G., Neuhäuser, M., Hatzelmann, A., Bethke, T. D., & Wurst, W. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011328 · Cited by 126
Peter, D., Jin, S.-L. C., Conti, M., Hatzelmann, A., & Zitt, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.4820 · Cited by 126
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells
Smith, S. J., Brookes-Fazakerley, S., Donnelly, L., Barnes, P. J., Barnette, M. S., & Giembycz, M. A. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00170.2002 · Cited by 122
Barber, R., Baillie, G. S., Bergmann, R., Shepherd, M. C., Sepper, R., Houslay, M. D., & Heeke, G. V. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00384.2003 · Cited by 121
Wang, H., Peng, M.-S., Chen, Y., Geng, J., Robinson, H. H., Houslay, M. D., Cai, J., & Ke, H. (2007) · Biochemical Journal · doi:10.1042/bj20070970 · Cited by 120
Assessing the emetic potential of PDE4 inhibitors in rats
Robichaud, A., Savoie, C., Stamatiou, P. B., Lachance, N., Jolicoeur, P., Rasori, R., & Chan, C. C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704457 · Cited by 120
Boswell‐Smith, V., Spina, D., Oxford, A. W., Comer, M., Seeds, E. A. M., & Page, C. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099192 · Cited by 116
Self-citationRennard, S. I., Schachter, N., Strek, M. E., Rickard, K., & Amit, O. (2006) · CHEST Journal · doi:10.1378/chest.129.1.56 · Cited by 113
Bousquet, J. J., Aubier, M., Sastre, J., Alonso, J. L. I., Adler, L. M., Hofbauer, P., Rost, K. ‐., Harnest, U., Kroemer, B., Albrecht, A. E., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00931.x · Cited by 109
Are phosphodiesterase 4 inhibitors just more theophylline?
Boswell‐Smith, V., Cazzola, M., & Page, C. P. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.045 · Cited by 107
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro
Jones, N. A., Boswell‐Smith, V., Lever, R., & Page, C. P. (2004) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2004.10.001 · Cited by 100
Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret
Robichaud, A., Tattersall, F. D., Choudhury, H., & Rodger, I. W. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00190-7 · Cited by 99
Fuhrmann, M., Jahn, H., Seybold, J., Neurohr, C., Barnes, P. J., Hippenstiel, S., Kraemer, H. J., & Suttorp, N. (1999) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.20.2.3140 · Cited by 97
Treatment of stable chronic obstructive pulmonary disease
Rennard, S. I. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16941-9 · Cited by 94
Kuss, H., Hoefgen, N., Johanssen, S., Kronbach, T., & Rundfeldt, C. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053942 · Cited by 87
Lim, S. K., Jatakanon, A., Gordon, D., Macdonald, C., Chung, K. F., & Barnes, P. J. (2000) · Thorax · doi:10.1136/thorax.55.10.837 · Cited by 87
Chan, S. C., Reifsnyder, D. H., Beavo, J. A., & Hanifin, J. M. (1993) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(93)90321-6 · Cited by 82
Gantner, F., Götz, C., Gekeler, V., Schudt, C., Wendel, A., & Hatzelmann, A. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701688 · Cited by 76
Sanz, M., Cortijo, J., Abu-Taha, M. I., Cerdá‐Nicolás, M., Schatton, E., Burgbacher, B., Klar, J., Tenor, H., Schudt, C., Issekutz, A. C., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707428 · Cited by 75
Gantner, F., Tenor, H., Gekeler, V., Schudt, C., Wendel, A., & Hatzelmann, A. (1997) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(97)70146-5 · Cited by 71
Martin‐Chouly, C., Astier, A., Jacob, C., Pruniaux, M., Bertrand, C., & Lagente, V. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.01.021 · Cited by 58
Novel signal transduction modulators for the treatment of airway diseases
Barnes, P. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.001 · Cited by 55
Aoki, M., Kobayashi, M., Ishikawa, J., Saita, Y., Terai, Y., Takayama, K., Miyata, K., & Yamada, T. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38895-0 · Cited by 53
Landells, L. J., Szilagyi, C. M., Jones, N. A., Banner, K. H., Allen, J. M., Doherty, A. M., O'Connor, B. J., Spina, D., & Page, C. P. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704120 · Cited by 43
Self-citationKung, T. T., Crawley, Y., Luo, B., Young, S. S., Kreutner, W., & Chapman, R. W. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703308 · Cited by 35
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD
Jones, N., Leport, M., Holand, T., Vos, T. P., Morgan, M., Fink, M., Pruniaux, M., Berthelier, C., O'Connor, B. J., Bertrand, C., et al. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.11.010 · Cited by 33
Ood, J. J. W., & Einberger, M. I. W. (1996) · Cited by 16
Cited by
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., & Whitebread, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3845 · Cited by 748
Fabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
Schafer, P., Parton, A., Gandhi, A., Capone, L., Adams, M., Wu, L., Bartlett, J., Loveland, M., Gilhar, A., Cheung, Y., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00559.x · Cited by 406
Burgin, A. B., Magnusson, O. T., Singh, J., Witte, P., Staker, B. L., Bjornsson, J. M., Thorsteinsdottir, M., Hrafnsdottir, S., Hagen, T., Kiselyov, A. S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 397
Metadata
- Authors
- Spina, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-10
- Volume
- 155
- Issue
- 3
- Pages
- 308-315
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2101175089
- Cited by
- 340
- References
- 65
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.